3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Thrombosis
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Docetaxel
43
enzalutamide
31
Prednisone
25
Abiraterone Acetate
24
Magnetic Resonance Spectroscopy
18
abiraterone
15
pembrolizumab
14
bicalutamide
14
Radiotherapy
14
Cyclophosphamide
13
darolutamide
12
Leuprolide
12
Goserelin
12
apalutamide
10
Ipilimumab
10
olaparib
9
Specimen Handling
9
Radiosurgery
9
Radiation
9
Injections
9
Biopsy
9
Pluvicto
8
Paclitaxel
8
Radiotherapy, Intensity-Modulated
7
Carboplatin
7
sargramostim
6
fludarabine
6
cabazitaxel
6
Sirolimus
6
Nivolumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Prostatic Neoplasms
×
Rivaroxaban
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled